Quotes 5-day view Delayed Nasdaq
1 106 907
1 462 061
733 000 Volume
Estimated financial data (e) (USD)
Net income 2021
Net Debt 2021
P/E ratio 2021
Net income 2022
Net Debt 2022
P/E ratio 2022
Capi. / Sales 2021
Capi. / Sales 2022
Nbr of Employees
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The CompanyÔÇÖs marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a...
Ratings of Verastem, Inc.
All news about VERASTEM, INC.
08:16a Verastem Oncology Appoints Michelle Robertson to Board of Directors - Form 8-K
08:14a VERASTEM, INC. : Change in Directors or Principal Officers, Financial Statements and Exhib..
07:01a Verastem Oncology Appoints Michelle Robertson to Board of Directors
09/30 Verastem Oncology Reports the Appointment of Louis J. Denis as Chief Medical Officer
09/24 VERASTEM ONCOLOGY : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/22 VERASTEM : Oncology Names Louis Denis Chief Medical Officer
09/22 VERASTEM ONCOLOGY : Appoints Louis J. Denis, M.D., as Chief Medical Officer
09/22 Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
09/20 Health Care Stocks Sink with Broader Markets
09/20 VERASTEM : Amgen to Evaluate VS-6766, Sotorasib Combo Therapy in Non-Small Cell Lung Cance..
09/20 Wall Street Futures Tumble as China's Evergrande Default Risk Weighs on Sentiment
09/20 Health Care Stocks Trade Lower Pre-Bell Monday
09/20 VERASTEM : Health Care
09/20 US Futures Fall, China's Evergrande Default Risk Weighs on Sentiment
09/20 VERASTEM : Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeu..
News in other languages on VERASTEM, INC.
Analyst Recommendations on VERASTEM, INC.
Technical analysis trends VERASTEM, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Number of Analysts
Last Close Price
Average target price
Spread / Average Target